Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Aims to Generate up to 80% of Revenues from Technology Licensing
CEO Chris Bunka says in audio interview that human study of company’s proprietary TurboCBD technology will start in April outside of North America Hopes to add 6-12 more IP technology licensing contracts within year Cutting-edge research designed to attract the attention of tobacco and cannabis industries Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) CEO Chris Bunka said in a recent audio interview that, although consumer products will always be important to LXRP, he estimates that up to 80 percent of its revenues could be generated through the licensing of its proprietary technology to other companies (http://nnw.fm/6sEoP). LXRP is a British…







